Monoclonal antibody 3F8

Drug Profile

Monoclonal antibody 3F8

Alternative Names: 3F8 MAb; MAb-3F8; MOAB 3F8; Murine 3F8 monoclonal antibody

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Neuroblastoma

Most Recent Events

  • 10 Mar 2010 Phase-II development is ongoing in USA
  • 31 Dec 2007 Monoclonal antibody 3F8 licensed to United Therapeutics Corporation worldwide
  • 31 Jan 2007 Memorial Sloan-Kettering Cancer Center initiates enrolment in a phase II trial for neuroblastoma in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top